[HTML][HTML] Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
A majority of cancers fail to respond to immunotherapy with antibodies targeting immune
checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 …
checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 …
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a …
J Bolaños-Meade, KR Cooke, CJ Gamper… - The Lancet …, 2019 - thelancet.com
Background Although severe haemoglobinopathies can be cured with allogeneic blood or
bone marrow transplantation, availability of matched donors and toxic effects can be …
bone marrow transplantation, availability of matched donors and toxic effects can be …
[HTML][HTML] Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide …
JA Kanakry, YL Kasamon, J Bolaños-Meade… - Biology of Blood and …, 2013 - Elsevier
Immunosuppressive regimens that effectively prevent graft-versus-host disease (GVHD)
after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an …
after allogeneic blood or marrow transplantation (allo-BMT) have been associated with an …
Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as …
IM Borrello, HI Levitsky, W Stock, D Sher… - Blood, The Journal …, 2009 - ashpublications.org
Preclinical models have demonstrated the efficacy of granulocyte-macrophage colony-
stimulating factor-secreting cancer immunotherapies (GVAX platform) accompanied by …
stimulating factor-secreting cancer immunotherapies (GVAX platform) accompanied by …
Immunotherapeutic approaches for hematologic malignancies
MA Caligiuri, A Velardi, DA Scheinberg… - ASH Education …, 2004 - ashpublications.org
The immune system has two complementary arms: one is older and seemingly more
primitive, called the innate immune system, found in both plants and animals. The second …
primitive, called the innate immune system, found in both plants and animals. The second …
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
Background Prevalence estimates for monoclonal gammopathy of undetermined
significance (MGUS) are based on predominantly White study populations screened by …
significance (MGUS) are based on predominantly White study populations screened by …
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
CG Kanakry, J Bolaños-Meade… - Blood, The Journal …, 2017 - ashpublications.org
The intensive and prolonged immunosuppressive therapy required to prevent or treat graft-
versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts …
versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts …
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to …
A Cuenca, F Cheng, H Wang, J Brayer, P Horna, L Gu… - Cancer research, 2003 - AACR
A better understanding of how solid malignancies arise in an immunocompetent host, avoid
immune recognition, and ultimately progress to widely disseminated cancer is essential to …
immune recognition, and ultimately progress to widely disseminated cancer is essential to …
[HTML][HTML] Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation
Inflammatory cytokines released by activated lymphocytes and innate cells in the context of
cellular therapy can cause fever, vasodilatation, and end-organ damage, collectively known …
cellular therapy can cause fever, vasodilatation, and end-organ damage, collectively known …
[HTML][HTML] Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation
PH Imus, AL Blackford, M Bettinotti, B Iglehart… - Biology of Blood and …, 2017 - Elsevier
Large alternative donor pools provide the potential for selecting a different donor for a
second allogeneic (allo) bone or marrow transplant (BMT). As HLA disparity may contribute …
second allogeneic (allo) bone or marrow transplant (BMT). As HLA disparity may contribute …